-Flow Cytometry (FLOW) Shared Resource The Flow Cytometry Shared Resource (FLOW SR) is a basic shared resource in the basic group that provides flow cytometry research support for Cancer Center members. The overall mission of the SR is to provide technical, educational assistance for individuals performing flow cytometry and to assist investigators in data interpretation and the planning of future experiments that involve flow cytometry. The SR provides multi-color flow cytometry analysis, high speed sorting (including biohazard sorting), education, consultation, application development, and data analysis. Since the 2010 review, use of the shared resource has increased 63%. To accommodate and permit this increase the SR has increased both hardware and staff. We added two analytical cytometers: a Stratedigm S1000EX for microparticle analysis, a 4-laser BD LSRFortessa, and two cell sorters: a BD FACSAria II SORP in BSL-2 containment and a FACSAria III for investigator operation. The FACSAria II, which is configured for BSL-2 sorting has been placed in a specially renovated BSL-2 space with enhanced precautions. We also upgraded the Beckman MoFlo XDP with two additional lasers. Education initiatives have expanded considerably, including user-operated cell sorting on the FACSAria III.
The Specific Aims focus on providing access and training on existing equipment, integrating new equipment, providing expert research staff and provided that continuing education to users on new experimental methods. We added a highly skilled Technology Manager position to accommodate the increased use and to provide additional services including expertise for the incoming Amnis ImageStreamX imaging flow cytometer. Center member usage accounted for 54% of the total SR usage and resulted in publications in journals such as JCI, JPET, and Blood. For 2015, the FLOW SR Facility requests $122,656 for personnel and maintenance expenses. CCSG funds are projected to be 19% of operating costs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Ghosh, Arunava; Coakley, Raymond C; Mascenik, Teresa et al. (2018) Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome. Am J Respir Crit Care Med 198:67-76
Gourevitch, Rebecca A; Rose, Sherri; Crockett, Seth D et al. (2018) Variation in Pathologist Classification of Colorectal Adenomas and Serrated Polyps. Am J Gastroenterol 113:431-439
Park, Eliza M; Deal, Allison M; Yopp, Justin M et al. (2018) Understanding health-related quality of life in adult women with metastatic cancer who have dependent children. Cancer 124:2629-2636
Kasoji, Sandeep K; Rivera, Judith N; Gessner, Ryan C et al. (2018) Early Assessment of Tumor Response to Radiation Therapy using High-Resolution Quantitative Microvascular Ultrasound Imaging. Theranostics 8:156-168
Klein, Brianna J; Krajewski, Krzysztof; Restrepo, Susana et al. (2018) Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers. Epigenetics 13:683-692
Brewer, Noel T; Hall, Marissa G; Noar, Seth M (2018) Pictorial cigarette pack warnings increase quitting: a comment on Kok et al. Health Psychol Rev 12:129-132
Birken, Sarah A; Rohweder, Catherine L; Powell, Byron J et al. (2018) T-CaST: an implementation theory comparison and selection tool. Implement Sci 13:143
Harrison, Emily B; Azam, Salma H; Pecot, Chad V (2018) Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment. Front Pharmacol 9:307
Keith, Benjamin P; Barrow, Jasmine B; Toyonaga, Takahiko et al. (2018) Colonic epithelial miR-31 associates with the development of Crohn's phenotypes. JCI Insight 3:
Cheng, Ning; Watkins-Schulz, Rebekah; Junkins, Robert D et al. (2018) A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight 3:

Showing the most recent 10 out of 1525 publications